Close Menu

NEW YORK (GenomeWeb News) – The international non-profit Drugs for Neglected Diseases Initiative (DNDi) and the Institut Pasteur Korea (IP-K) will collaborate to screen for and examine molecules that may be used as new treatments for certain "neglected" diseases, IP-K said today.

The two-year research agreement will focus on studying molecules that could be developed into treatments for leishmaniasis, which kills around 20,000 to 30,000 people per year, and Chagas disease, which affects around seven to eight million people every year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.

Aug
29
Sponsored by
PerkinElmer

This webinar will outline how RUCDR Infinite Biologics, the world's largest university-based biorepository, has implemented workflows and processes to support precision medicine applications.